- Conditions
- Anemia, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Drug Toxicity, Radiation Toxicity, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
- Interventions
- External Beam Radiation Therapy, Cisplatin, Internal Radiation Therapy, Epoetin Alfa
- Radiation · Drug · Biological
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- Female only
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 97–120
of 218
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mucositis, Graft-versus-host Disease
- Interventions
- Tac+MTX, TAC + MMF
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Anemia, Iron-Deficiency, Kidney Failure, Chronic
- Interventions
- Sodium Ferric Gluconate complex in sucrose, Ferrous sulfate tablets
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 20 more
- Conditions
- Sickle Cell Disease, Kidney Failure, Chronic
- Interventions
- Not listed
- Lead sponsor
- Kenneth Ataga MD
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 3
- States / cities
- Chapel Hill, North Carolina • Columbus, Ohio • Memphis, Tennessee
- Conditions
- Anemia
- Interventions
- Ferric Carboxymaltose (FCM)
- Drug
- Lead sponsor
- American Regent, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Norristown, Pennsylvania
- Conditions
- Anemia of Chronic Kidney Disease
- Interventions
- Erythropoiesis-Stimulating Agent (ESA), Vadadustat
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 18
- States / cities
- Montgomery, Alabama • Hartford, Connecticut • Middlebury, Connecticut + 9 more
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Interventions
- peginesatide, Epoetin Alfa
- Drug
- Lead sponsor
- Affymax
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 803 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 89
- States / cities
- Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more
- Conditions
- Renal Anemia
- Interventions
- FG2216
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 27
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
- Conditions
- Anaemia, Aspergillosis, Allergic Bronchopulmonary
- Interventions
- Daprodustat, rhEPO, Placebo, Iron therapy
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 2,964 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 126
- States / cities
- Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more
- Conditions
- Anemia in Chronic Kidney Disease Patients Not on Dialysis
- Interventions
- Darbepoetin alfa, Placebo
- Biological · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 756 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 243
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 198 more
- Conditions
- Anemia
- Interventions
- Epoetin alfa 3 times weekly /once weekly, Epoetin alfa once weekly, Epoetin alfa once every two weeks
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 61
- States / cities
- Glendale, Arizona • Tempe, Arizona • Chula Vista, California + 58 more
- Conditions
- Thrombotic Microangiopathies
- Interventions
- OMS721
- Biological
- Lead sponsor
- Omeros Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 5
- States / cities
- Duarte, California • Rochester, Minnesota • New York, New York + 2 more
- Conditions
- Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Interventions
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- Up to 74 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 2
- States / cities
- San Francisco, California • Winston-Salem, North Carolina
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Pegcetacoplan
- Drug
- Lead sponsor
- Apellis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Miami Lakes, Florida • Louisville, Kentucky + 4 more
- Conditions
- Anemia, Chronic Kidney Disease, Kidney Disease
- Interventions
- Darbepoetin Alfa, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 36 more
- Conditions
- Sickle Cell Anemia
- Interventions
- Ambrisentan, Placebo
- Drug
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Iron-deficiency, Pregnancy, High Risk, Stress, Psychological
- Interventions
- Probiotic LP299v 10x10 colony forming units in capsule form, Placebo in capsule form
- Dietary Supplement · Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Fanconi Anemia Complementation Group A
- Interventions
- RP-L102
- Biological
- Lead sponsor
- Rocket Pharmaceuticals Inc.
- Industry
- Eligibility
- 1 Year to 12 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Interventions
- peginesatide, Epoetin alfa or Epoetin beta
- Drug
- Lead sponsor
- Affymax
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 823 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • McGehee, Arkansas + 33 more
- Conditions
- Anemia, Renal Insufficiency, Chronic
- Interventions
- Molidustat (BAY 85-3934), Epoetin alfa/beta
- Drug · Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 30
- States / cities
- Azusa, California • Long Beach, California • Los Angeles, California + 21 more
- Conditions
- Anemia, Renal Insufficiency, Chronic
- Interventions
- Molidustat (BAY85-3934), Epoetin alfa/beta
- Drug · Biological
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 23
- States / cities
- Azusa, California • Long Beach, California • Lynwood, California + 16 more
- Conditions
- Sickle Cell Disease Vaso-occlusive Crisis
- Interventions
- CSL889, Placebo
- Biological · Drug
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Oakland, California • Orange, California • Washington D.C., District of Columbia + 15 more
- Conditions
- Atypical Hemolytic Uremic Syndrome
- Interventions
- Crovalimab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 28 Days to 17 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Omaha, Nebraska • Hackensack, New Jersey
- Conditions
- Anemia, Chronic Kidney Disease (CKD)
- Interventions
- HX575 epoetin alfa, US-licensed epoetin alfa
- Drug
- Lead sponsor
- Sandoz
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 52
- States / cities
- Tempe, Arizona • Azusa, California • Bakersfield, California + 42 more